159 related articles for article (PubMed ID: 37528632)
1. Clinical factors for tumor response, progression, and survival in nivolumab for advanced renal cell carcinoma in the SNiP-RCC study.
Blas L; Shiota M; Miyake H; Takahashi M; Oya M; Tsuchiya N; Masumori N; Matsuyama H; Obara W; Shinohara N; Fujimoto K; Nozawa M; Ohba K; Ohyama C; Hashine K; Akamatsu S; Kamba T; Mita K; Gotoh M; Tatarano S; Fujisawa M; Tomita Y; Mukai S; Ito K; Tanegashima T; Tokunaga S; Eto M;
Int J Urol; 2023 Sep; 30(9):788-796. PubMed ID: 37528632
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma.
Brown LC; Zhu J; Desai K; Kinsey E; Kao C; Lee YH; Pabla S; Labriola MK; Tran J; Dragnev KH; Tafe LJ; Dayyani F; Gupta RT; McCall S; George DJ; Glenn ST; Nesline MK; George S; Zibelman M; Morrison C; Ornstein MC; Zhang T
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36252996
[TBL] [Abstract][Full Text] [Related]
3. Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer Patients.
Basak EA; van der Meer JWM; Hurkmans DP; Schreurs MWJ; Oomen-de Hoop E; van der Veldt AAM; Bins S; Joosse A; Koolen SLW; Debets R; Peeters RP; Aerts JGJV; Mathijssen RHJ; Medici M
Thyroid; 2020 Jul; 30(7):966-973. PubMed ID: 32151195
[No Abstract] [Full Text] [Related]
4. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
5. Effect of genetic polymorphisms on outcomes following nivolumab for advanced renal cell carcinoma in the SNiP-RCC trial.
Shiota M; Miyake H; Takahashi M; Oya M; Tsuchiya N; Masumori N; Matsuyama H; Obara W; Shinohara N; Fujimoto K; Nozawa M; Ohba K; Ohyama C; Hashine K; Akamatsu S; Kamba T; Mita K; Gotoh M; Tatarano S; Fujisawa M; Tomita Y; Mukai S; Ito K; Tanegashima T; Tokunaga S; Eto M;
Cancer Immunol Immunother; 2023 Jun; 72(6):1903-1915. PubMed ID: 36729213
[TBL] [Abstract][Full Text] [Related]
6. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
7. Impact of Body Mass Index on Outcomes in an Asian population of Advanced Renal Cell Carcinoma and Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors.
Ishihara H; Ishiyama Y; Nemoto Y; Nakamura K; Tachibana H; Fukuda H; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Tanabe K; Kondo T; Takagi T
Clin Genitourin Cancer; 2023 Feb; 21(1):136-145. PubMed ID: 36031535
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of immune-related adverse events in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab.
Ikeda T; Ishihara H; Nemoto Y; Tachibana H; Fukuda H; Yoshida K; Takagi T; Iizuka J; Hashimoto Y; Ishida H; Kondo T; Tanabe K
Urol Oncol; 2021 Oct; 39(10):735.e9-735.e16. PubMed ID: 34172370
[TBL] [Abstract][Full Text] [Related]
9. The association between antibiotic use and survival in renal cell carcinoma patients treated with immunotherapy: a multi-center study.
Guven DC; Acar R; Yekeduz E; Bilgetekin I; Baytemur NK; Erol C; Ceylan F; Sendur MA; Demirci U; Urun Y; Karadurmus N; Erman M; Kilickap S
Curr Probl Cancer; 2021 Dec; 45(6):100760. PubMed ID: 34130864
[TBL] [Abstract][Full Text] [Related]
10. Low-Dose Nivolumab in Renal Cell Carcinoma: A Real-World Experience.
Zhao JJ; Kumarakulasinghe NB; Muthu V; Lee M; Walsh R; Low JL; Choo J; Tan HL; Chong WQ; Ang Y; Chan G; Yong WP; Huang Y; Ngoi N; Wong A
Oncology; 2021; 99(3):192-202. PubMed ID: 33440374
[TBL] [Abstract][Full Text] [Related]
11. Site-specific Response to Nivolumab in Renal Cell Carcinoma.
Negishi T; Furubayashi N; Nakagawa T; Nishiyama N; Kitamura H; Hori Y; Kuroiwa K; Son Y; Seki N; Tomoda T; Okajima E; Nakamura M
Anticancer Res; 2021 Mar; 41(3):1539-1545. PubMed ID: 33788747
[TBL] [Abstract][Full Text] [Related]
12. Real-world Data of Nivolumab for Patients With Advanced Renal Cell Carcinoma in the Netherlands: An Analysis of Toxicity, Efficacy, and Predictive Markers.
Verhaart SL; Abu-Ghanem Y; Mulder SF; Oosting S; Van Der Veldt A; Osanto S; Aarts MJB; Houtsma D; Peters FPJ; Groenewegen G; Van Herpen CML; Pronk LM; Tascilar M; Hamberg P; Los M; Vreugdenhil G; Polee M; Ten Tije AJ; Haanen JBAG; Bex A; van den Eertwegh AJ
Clin Genitourin Cancer; 2021 Jun; 19(3):274.e1-274.e16. PubMed ID: 33317946
[TBL] [Abstract][Full Text] [Related]
13. Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors.
Gul A; Stewart TF; Mantia CM; Shah NJ; Gatof ES; Long Y; Allman KD; Ornstein MC; Hammers HJ; McDermott DF; Atkins MB; Hurwitz M; Rini BI
J Clin Oncol; 2020 Sep; 38(27):3088-3094. PubMed ID: 32491962
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Axitinib After Nivolumab Failure in Metastatic Renal Cell Carcinoma.
Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Okumi M; Ishida H; Tanabe K
In Vivo; 2020; 34(3):1541-1546. PubMed ID: 32354960
[TBL] [Abstract][Full Text] [Related]
15. FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy.
Choueiri TK; Kluger H; George S; Tykodi SS; Kuzel TM; Perets R; Nair S; Procopio G; Carducci MA; Castonguay V; Folefac E; Lee CH; Hotte SJ; Miller WH; Saggi SS; Lee CW; Desilva H; Bhagavatheeswaran P; Motzer RJ; Escudier B
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36328377
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of immune checkpoint inhibitors in elderly patients with metastatic renal cell carcinoma.
Nemoto Y; Ishihara H; Nakamura K; Tachibana H; Fukuda H; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Tanabe K; Kondo T; Takagi T
Int Urol Nephrol; 2022 Jan; 54(1):47-54. PubMed ID: 34704214
[TBL] [Abstract][Full Text] [Related]
17. C-reactive protein and neutrophil-lymphocyte ratio are prognostic in metastatic clear-cell renal cell carcinoma patients treated with nivolumab.
Roussel E; Kinget L; Verbiest A; Debruyne PR; Baldewijns M; Van Poppel H; Albersen M; Beuselinck B
Urol Oncol; 2021 Apr; 39(4):239.e17-239.e25. PubMed ID: 33485762
[TBL] [Abstract][Full Text] [Related]
18. Real-World Data on the Use of Nivolumab Monotherapy in the Treatment of Advanced Renal Cell Carcinoma after Prior Therapy: Interim Results from the Noninterventional NORA Study.
Grimm MO; Grünwald V; Müller-Huesmann H; Ivanyi P; Schostak M; von der Heyde E; Schultze-Seemann W; Belz H; Bögemann M; Wang M; Herber M; Bedke J;
Eur Urol Focus; 2022 Sep; 8(5):1289-1299. PubMed ID: 34953677
[TBL] [Abstract][Full Text] [Related]
19. A Multi-institutional, Retrospective Analysis of Patients with Metastatic Renal Cell Carcinoma to Bone Treated with Combination Ipilimumab and Nivolumab.
Desai K; Brown L; Wei W; Tucker M; Kao C; Kinsey E; Rini B; Beckermann K; Zhang T; Ornstein MC
Target Oncol; 2021 Sep; 16(5):633-642. PubMed ID: 34379283
[TBL] [Abstract][Full Text] [Related]
20. mTOR and mTOR phosphorylation status in primary and metastatic renal cell carcinoma tissue: differential expression and clinical relevance.
Rausch S; Schollenberger D; Hennenlotter J; Stühler V; Kruck S; Stenzl A; Bedke J
J Cancer Res Clin Oncol; 2019 Jan; 145(1):153-163. PubMed ID: 30368665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
